Selected Publications:
Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, Evans TL, Langer CJ: Determinants of Survival in Advanced Non-Small Cell Lung Cancer in the Era of Targeted Therapies Clinical Lung Cancer : 2013.
Aggarwal, C: Nab-paclitaxel is a valuable NSCLC therapy option Community Oncology 10 (6): 2013.
Aggarwal C, Dahlberg SE, Hanna N, Kolesar J, Hirsch FR, Ramalingam SS and Schiller JH: Exploratory biomarker analyses from ECOG 4508: Three-arm randomized phase II study of carboplatin and paclitaxel in combination with cetuximab, IMC-A12, or both for advanced non-small cell lung cancer patients Journal of Clinical Oncology 31s (abstr 8106): 2013.
Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, Evans TL, Langer CJ: Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: Do disparities exist? Lung Cancer : 2013.
Lustgarten DS, Deshpande C, Aggarwal C, Wang LC, Saloura V, Vachani A, Wang LP, Litzky L, Feldman M, Creaney J, Nowak AK, Langer CJ, Inghilleri S, Stella G, Albelda SM
: Thymidylate Synthase and Folyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma
Journal of Thoracic Oncology
Volume 8 (4) : 469–477,2013.
Aggarwal, C and Langer, CJ: Recent advances in the management of advanced Non Small Cell Lung Cancer Community Oncology 10 (4): 2013.
Aggarwal C, Meropol N J, Punt C J, Iannotti N, Saidman B H, Sabbath K D, Gabrail N Y, Picus J, Morse M A, Mitchell E, Miller M C, Cohen S J: Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 24 (2): 420-8,2013.
Aggarwal C, Ranganathan A, Lustgarten DS et al: Circulating Tumor Cells In Patients With Small Cell Lung Cancer: A Marker Of Disease Burden, Therapeutic Response, And Predictor Of Disease Relapse Journal of Thoracic Oncology : 2012.
Brady A, McNeill JD, Judy B, Evans T, Cohen RB, Langer C, Vachani A AND Aggarwal C: Survival outcome segregated by KRAS mutation status in newly diagnosed stage IV non-small cell lung cancer patients treated with first-line chemotherapy Journal of Clinical Oncology Supplement : 2012.
Ranganathan A, Schwed-Lustgarten D, Aggarwal C et al: Circulating tumor cells in patients with small cell lung cancer: a marker of disease burden, therapeutic response, and predictor of disease relapse Journal of Clinical Oncology Supplement : 2012.